WallStreetZen

NYSE: BMY
Bristol Myers Squibb Co Stock Forecast, Predictions & Price Target

Analyst price target for BMY

Based on 5 analysts offering 12 month price targets for Bristol Myers Squibb Co.
Min Forecast
$70.00+11.8%
Avg Forecast
$72.60+15.96%
Max Forecast
$76.00+21.39%

Should I buy or sell BMY stock?

Buy
Strong Buy
2 analysts 40%
Buy
2 analysts 40%
Hold
1 analysts 20%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

BMY stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDate
Justin Smith
Societe Generale
Strong BuyUpgrades$76.00+21.39%2020-11-16
Seamus Fernandez
Guggenheim
Strong BuyUpgrades$70.00+11.80%2020-10-19
Dane Leone
Raymond James
BuyInitiates Coverage On$75.00+19.79%2020-07-28
Sel Hardy
CFRA
BuyMaintains$70.00+11.80%2020-05-07
Anonymous
Bernstein
HoldReinstates$72.00+15.00%2020-11-10

1 of 1

Forecast return on equity

Is BMY forecast to generate an efficient return?
Company
51.68%
Industry
76.5%
Market
32,369.88%
BMY's Return on Equity is forecast to be high in 3 years (51.68%); analysts are confident in the firm's ability to efficiently generate return on equity
Forecast

Forecast return on assets

Is BMY forecast to generate an efficient return on assets?
Company
16.5%
Industry
16.91%
Market
11,660.33%
BMY is forecast to generate lower Return on Assets (16.5%) than the US Drug Manufacturers - General industry average (16.91%)
Forecast

BMY earnings per share forecast

What is BMY's earnings per share in the next 3 years based on estimates from 8 analysts?
Avg 1 year Forecast
$7.45-286.59%
Avg 2 year Forecast
$8.05-301.65%
Avg 3 year Forecast
$8.44-311.63%

BMY revenue forecast

What is BMY's revenue in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
$46.0B+8.15%
Avg 2 year Forecast
$47.8B+12.45%
Avg 3 year Forecast
$49.4B+16.29%
BMY's revenue is forecast to grow at a rate of 5.16% per year, which is not exceptional
Forecast

BMY revenue growth forecast

How is BMY forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
5.16%
Industry
5.95%
Market
15.05%
BMY's revenues are forecast to grow slower (5.16% per year) than the US Drug Manufacturers - General industry average (5.95%)
Forecast
BMY's revenues are forecast to grow slower (5.16% per year) than the US market average (15.05%)
Forecast

Bristol Myers Squibb Stock Forecast FAQ

Is Bristol Myers Squibb Stock a good buy in 2021, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NYSE: BMY) stock is to Buy BMY stock.

Out of 5 analysts, 2 (40%) are recommending BMY as a Strong Buy, 2 (40%) are recommending BMY as a Buy, 1 (20%) are recommending BMY as a Hold, 0 (0%) are recommending BMY as a Sell, and 0 (0%) are recommending BMY as a Strong Sell.

What is BMY's earnings growth forecast for 2021-2023?

(NYSE: BMY) Bristol Myers Squibb's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 33.91%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 23.13%.

Bristol Myers Squibb's earnings in 2021 is -$9,015,000,000.On average, 8 Wall Street analysts forecast BMY's earnings for 2021 to be $16,823,850,052, with the lowest BMY earnings forecast at $16,518,783,597, and the highest BMY earnings forecast at $17,241,904,082. On average, 7 Wall Street analysts forecast BMY's earnings for 2022 to be $18,181,282,788, with the lowest BMY earnings forecast at $17,626,061,840, and the highest BMY earnings forecast at $18,688,145,054.

In 2023, BMY is forecast to generate $19,081,341,818 in earnings, with the lowest earnings forecast at $18,258,792,265 and the highest earnings forecast at $20,360,361,177.

What is BMY's revenue growth forecast for 2021-2023?

(NYSE: BMY) Bristol Myers Squibb's forecast annual revenue growth rate of 5.16% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 5.95%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 15.05%.

Bristol Myers Squibb's revenue in 2021 is $42,518,000,000.On average, 5 Wall Street analysts forecast BMY's revenue for 2021 to be $103,911,871,463,348, with the lowest BMY revenue forecast at $102,994,050,786,797, and the highest BMY revenue forecast at $104,540,624,725,716. On average, 5 Wall Street analysts forecast BMY's revenue for 2022 to be $108,040,175,355,558, with the lowest BMY revenue forecast at $105,672,669,846,173, and the highest BMY revenue forecast at $110,694,380,059,534.

In 2023, BMY is forecast to generate $111,732,035,359,084 in revenue, with the lowest revenue forecast at $110,149,327,993,392 and the highest revenue forecast at $115,156,937,357,280.

What is BMY's forecast return on assets (ROA) for 2021-2024?

(NYSE: BMY) forecast ROA is 16.5%, which is lower than the forecast US Drug Manufacturers - General industry average of 16.91%.

What is BMY's Price Target?

According to 5 Wall Street analysts that have issued a 1 year BMY price target, the average BMY price target is $72.60, with the highest BMY stock price forecast at $76.00 and the lowest BMY stock price forecast at $70.00.

On average, Wall Street analysts predict that Bristol Myers Squibb's share price could stay at $72.60 by Nov 16, 2021. The average Bristol Myers Squibb stock price prediction forecasts a potential downside of N/A from the current BMY share price of $62.61.

What is BMY's Earnings Per Share (EPS) forecast for 2021-2023?

(NYSE: BMY) Bristol Myers Squibb's current Earnings Per Share (EPS) is -$3.99. On average, analysts forecast that BMY's EPS will be $7.45 for 2021, with the lowest EPS forecast at $7.31, and the highest EPS forecast at $7.63. On average, analysts forecast that BMY's EPS will be $8.05 for 2022, with the lowest EPS forecast at $7.80, and the highest EPS forecast at $8.27. In 2023, BMY's EPS is forecast to hit $8.44 (min: $8.08, max: $9.01).

What is BMY's forecast return on equity (ROE) for 2021-2024?

(NYSE: BMY) forecast ROE is 51.68%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.